brain-cancer

Ferroptosis regulators in glioma identified as potential drug targets using bioinformatics.

Using GEO database gene expression profiles and the FerrDb ferroptosis gene database, 10 hub genes were identified in glioma: TP53, RRM2, EZH2, CDKN1A, MYCN, KIF20A, BLM, GLS2, HMOX1, and GOT1. Ferroptosis linked to p53 signaling, apoptosis, and immune regulation. Molecular docking confirmed good…

Ferroptosis regulators in glioma identified as potential drug targets using bioinformatics.

Key Findings

10 ferroptosis hub genes identified in glioma: TP53, RRM2, EZH2, CDKN1A, MYCN, KIF20A, BLM, GLS2, HMOX1, GOT1
Ferroptosis links to p53 signaling, apoptosis, and reactive oxygen metabolism
Significant immune cell infiltration differences between glioma subtypes
Molecular docking shows good binding between drug candidates and hub targets
qRT-PCR validated differential expression in glioma cell lines

Implications

These ferroptosis-related hub genes provide a starting point for targeted drug development in glioma. EZH2 inhibitors could be repurposed.

Caveats

Bioinformatics + cell line validation; abstract-only. Computational predictions require extensive experimental and clinical validation.

Source: Medicine — 2026-04-10

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Ferroptosis regulators in glioma identified as potential drug targets using bioinformatics.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database